Dasatinib in Treating Patients with Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Solar Melanoma that Cannot Be Removed by Surgery

Article

The aim of this clinical trial is to study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery.

Study Type: Interventional

Age/Sex Requirement: 18 years+ (None)

Sponsor: Eastern Cooperative Oncology Group

ClinicalTrials.gov Identifier: NCT00700882

Purpose: To study how well dasatinib works in treating patients with locally advanced or metastatic mucosal melanoma, acral melanoma, or solar melanoma that cannot be removed by surgery. The primary outcome measure is objective tumor response rate. Secondary outcomes measures include response duration, progression-free survival, and safety profile.

Click here for more information about the clinical trial.

Related Videos
Katie Ross-Driscoll, PhD, MPH | Credit: Regenstrief Institute
Video 3 -  4 KOLs are featured in, "Collaborating with Specialists: Primary Care Clinician’s Evolving Role in HE Management"
Video 3 -  4 KOLs are featured in, "HE Experts on Symptoms, Risk Factors, Diagnosis Challenges, and Severity Grading"
Shauna Applin, ARNP, an expert on HIV
© 2024 MJH Life Sciences

All rights reserved.